New guidelines, growth opportunities, and investment in new technologies

Our Press & Policy

Stay up to date with the latest IVD sector news and developments in health policy.

07Feb

Member Press Release: OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park

07 Feb, 2024 | Return|

Oxford, UK – 07 February 2024. OGT, a leading global provider of genomic research and diagnostic solutions, proudly announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration.

 

"This is an exciting time of growth and development for us. As a leader in genomics research and diagnostics solutions, we are thrilled to celebrate the opening of our advanced facility in the heart of the Oxford Innovation Quarter," said Adrian Smith, CEO of OGT. "From here, we can accelerate our next phase of product development and global expansion – providing our customers with greater access to leading-class products and tailored solutions backed by extensive collaboration and support."

 

As part of the enhanced services at the new facility, customers will benefit from face-to-face support with OGT's field application specialists within the new show lab. Here, the scientific team can give in-depth demonstrations for both NGS and FISH products, proving the capabilities of the company’s unique hybridisation technology. Designed in collaboration with recognised cancer experts, OGT’s SureSeq NGS panels offer unparalleled coverage completeness and uniformity, allowing accurate detection of key genetic aberrations in a wide range of haematological and solid tumour cancers. By collaborating closely with customers, OGT can help to progress the future of genetic-based medicine, providing comprehensive solutions tailored to the unique needs of its diverse customer base.

 

Investment Minister, Lord Dominic Johnson also commented on OGT’s expansion, “The UK is recognised as a world leader in life sciences and this multi-million-pound investment and expansion by OGT is another vote of confidence for our plan to grow the economy, increase prosperity and support jobs across the country. I am delighted that this larger, state-of-the-art site at the Oxford Technology Park will grow to bring together the best of investment and expertise, making the most of what the UK has to offer.”

 

For further information, please contact:

Oxford Technology Park, 4A Technology Drive, Kidlington, Oxfordshire, OX5 1GN, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

 

Editor’s notes

About OGT

OGT, a Sysmex group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at www.ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

 

 

 

 

 

Interested in becoming a member? Join us!

Copyright 2023 BIVDA Ltd is registered in England
Company Number 2687137
Registered Office is 299 Oxford Street (5th floor),
London, W1C 2DZ. VAT Number 563105858